Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Macrophage activation syndrome
Questions discussed in this category
How do you approach management of a patient with persistent EBV infection and MAS despite treatment with Rituximab, anakinra and canakinumab?
Would you consider alternative B cell depleting therapies such as ofatumumab or ocrelizumab?
1 Answer available
What is the difference between Multisystem Inflammatory Syndrome in Adults (MIS-A) and MAS/HLH?
1 Answer available
Do you recommend using IL-1/IL-6 inhibitors in COVID-19 multisystem inflammatory syndrome in adults (MIS-A)?
1 Answer available
18491
12549
8533
Papers discussed in this category
ACR Open Rheumatol, 2021 Aug 25
Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.
Related Topics
Rheumatology
COVID-19
Autoinflammatory disorders
General Rheumatology
IL-6 Inhibitors
IL-1 Inhibitors
HLH
COVID-19 virus
Rituximab